According to a statement on the official website of British American Tobacco (BAT), the company has established an innovation center at its global research and development (R&D) headquarters in Southampton. This center will play a key role in the company's ongoing transformation and in pursuing its vision of creating a "better future".
A facility costing £30 million has enhanced and deepened the research and development capabilities of British American Tobacco, providing nine specially designed technology spaces to help develop the company's low-risk product portfolio. The Innovation Centre is dedicated to researching modern oral nicotine pouches, vape liquids and flavors, heated products, as well as new products beyond nicotine.
This investment will also support work in packaging, engineering, innovation development, and system integration.
The British American Tobacco Company's factory in Southampton has been the location of its research and development operations since 1956. It is one of the largest employers in the region, currently employing over 1,000 staff members from various parts of the UK. Its local supply chain includes over 25 suppliers, spread across more than 30 countries and regions.
British American Tobacco has more than 1,600 research and development experts in countries such as the UK, US, Brazil, Indonesia, Malaysia, and China. In 2021, the company opened an innovation center in Trieste, Italy, and in 2022, in Shenzhen, China. British American Tobacco invests 3 billion pounds annually in research and development to develop new category products and establish evidence.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
![[2Firsts Special Report] EPO Enlarged Board of Appeal Issues Key Decision: China YTI Gains Procedural Advantage in Heated Tobacco Patent Dispute with Philip Morris](https://static.2firsts.com/uploads/20250619/680a1f4818d125725c6608db46873b7a.png?x-oss-process=style/origin)
![[Breaking] Juul’s Device and 4 Pod Products Officially Authorized by FDA, Reenters the U.S. Regulated Market](https://static.2firsts.com/uploads/20241113/34ffc17feb2b6076367c9e5f413641f2.jpg?x-oss-process=style/origin)